Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (671-680 of 962) with videos related to

Pageof 97
Sort By:
European Heart Journal. Cardiovascular Pharmacotherapy|December 17, 2019
Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS studyChun Chin Chang, Ply Chichareon, Rodrigo Modolo, et al.
Circulation|September 25, 2023
Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized TrialsBehnood Bikdeli, David Erlinge, Marco Valgimigli, et al.
JACC. Cardiovascular Interventions|July 9, 2016
Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS RegistryUsman Baber, George Dangas, Jaya Chandrasekhar, et al.
JAMA|March 30, 2016
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary InterventionRobert W Yeh, Eric A Secemsky, Dean J Kereiakes, et al.
International Journal of Cardiology|September 17, 2020
Regional variation in patients and outcomes in the GLOBAL LEADERS trialChao Gao, Kuniaki Takahashi, Scot Garg, et al.
European Journal of Heart Failure|September 2, 2022
Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trialOtavio Berwanger, Marc Pfeffer, Brian Claggett, et al.
JAMA|January 11, 2022
Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical TrialNeil A Goldenberg, John M Kittelson, Thomas C Abshire, et al.
International Journal of Cardiology|April 26, 2018
Incidence, determinants and clinical impact of definite stent thrombosis on mortality in women: From the WIN-DES collaborative patient-level pooled analysisLaura S Kerkmeijer, Bimmer E Claessen, Usman Baber, et al.
Circulation|December 1, 2025
Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary SyndromeSotirios Tsimikas, Michael Szarek, Christa M Cobbaert, et al.
Circulation|November 25, 2016
Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I)C Michael Gibson, Serge Korjian, Pierluigi Tricoci, et al.
Pageof 97

Showing results (671-680 of 962) with videos related to

Sort By:
Pageof 97
European Heart Journal. Cardiovascular Pharmacotherapy|December 17, 2019
Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS studyChun Chin Chang, Ply Chichareon, Rodrigo Modolo, et al.
Circulation|September 25, 2023
Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized TrialsBehnood Bikdeli, David Erlinge, Marco Valgimigli, et al.
JACC. Cardiovascular Interventions|July 9, 2016
Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS RegistryUsman Baber, George Dangas, Jaya Chandrasekhar, et al.
JAMA|March 30, 2016
Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary InterventionRobert W Yeh, Eric A Secemsky, Dean J Kereiakes, et al.
International Journal of Cardiology|September 17, 2020
Regional variation in patients and outcomes in the GLOBAL LEADERS trialChao Gao, Kuniaki Takahashi, Scot Garg, et al.
European Journal of Heart Failure|September 2, 2022
Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trialOtavio Berwanger, Marc Pfeffer, Brian Claggett, et al.
JAMA|January 11, 2022
Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical TrialNeil A Goldenberg, John M Kittelson, Thomas C Abshire, et al.
International Journal of Cardiology|April 26, 2018
Incidence, determinants and clinical impact of definite stent thrombosis on mortality in women: From the WIN-DES collaborative patient-level pooled analysisLaura S Kerkmeijer, Bimmer E Claessen, Usman Baber, et al.
Circulation|December 1, 2025
Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary SyndromeSotirios Tsimikas, Michael Szarek, Christa M Cobbaert, et al.
Circulation|November 25, 2016
Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I)C Michael Gibson, Serge Korjian, Pierluigi Tricoci, et al.
Pageof 97